Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
14.19 | -0.39 (-2.67%) |
| Exchange : | NASDAQ (US Dollar) |
| Ric Code : | ORMP |
| Volume : | 488,140 |
| Date : | 07-30-2021 |
* Minimum 20 minute delay See terms
–
Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]
Oramed Pharmaceuticals Appoints Chief Commercial Officer
NEW YORK, July 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Michael Rabinowitz [...]
Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial
- Oravax's virus-like particle (VLP) vaccine being tested against COVID-19 variants including Delta - Oravax signs licensing deal for VLP injectable vaccine technology with Premas Biotech for commercialization in India NEW YORK, July 21, 2021 [...]
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
NEW YORK, June 22, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it is set to join [...]
Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study
First and Largest of two concurrent Phase 3 trials on track to complete randomization by Q4 2021 NEW YORK, June 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical [...]
Investors Tools